TABLE 3.
Selected correlates of the 12 months post-HAART level and the change, adjusted for baseline, from pre-HAART to 12 months for TC, LDL and HDL levels among infants with 12 months of follow-up.
| TC mg/dL N=68 |
LDL mg/dL N=62 |
HDL mg/dL N=70 |
|||||
|---|---|---|---|---|---|---|---|
| Correlate | N* | 12 Month Mean^ |
Adjusted Mean Change¶ |
12 Month Mean^ |
Adjusted Mean Change¶ |
12 Month Mean^ |
Adjusted Mean Change¶ |
| Overall Mean | 158.9 | 39.4 | 80.2 | 26.9 | 48.3 | 16.6 | |
| Females | 36 | 155.0 | 33.8 | 78.4 | 21.7 | 44.8 | 10.9 |
| Males | 32 | 163.3 | 45.6 | 82.3 | 29.0 | 52.2¥ | 18.9¥ |
| Age <4 months | 36 | 169.7 | 46.6 | 91.5 | 35.0 | 47.0 | 13.9 |
| Age ≥4 months | 32 | 146.8 | 25.7 | 66.5¥ | 10.0¥ | 49.7 | 17.2 |
| WHO Stage 1/2 | 38 | 148.8 | 27.7 | 74.6 | 16.7 | 44.0 | 11.2 |
| WHO Stage 3/4 | 28 | 168.1 | 47.1 | 83.6 | 28.7 | 53.2‡ | 20.2‡ |
| Pre-HAART WAZ ≥-2 | 35 | 148.1 | 23.5 | 73.3 | 14.4 | 45.3 | 12.3 |
| Pre-HAART WAZ <-2 | 33 | 170.4§ | 52.3¥ | 87.5 | 34.7§ | 51.5§ | 18.4§ |
| Pre-HAART HAZ ≥-2 | 39 | 154.9 | 31.2 | 79.2 | 20.3 | 46.3 | 14.2 |
| Pre-HAART HAZ <-2 | 29 | 164.4 | 44.8 | 81.6 | 26.5 | 50.7 | 17.8 |
| NVP-based regimen | 40 | 164.9 | 43.9 | 83.5 | 26.7 | 51.9 | 20.9 |
| LPV/r-based regimen | 28 | 150.30.3 | 028.6.3 | 075.0.4 | 15.8 | 42.9‡ | 10.7¤ |
Number of study participants for analyses of TC. Total N for other lipids were similar.
P-values refer to linear regression analyses used to evaluate potential correlates of 12-month lipid levels.
P-values refer to linear regression analyses used to evaluate potential correlates of the change in lipid level from pre-HAART to 12 months, after adjusting for pre-HAART lipid level; mean change was derived from these models.
0.05>P<0.1.
0.01>P<0.05.
0.005>P≤0.01.
P<0.005.
HAART indicates highly active antiretroviral therapy; WAZ weight-for-age Z-score; HAZ, height-for-age Z-score; TC, total cholesterol, LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; TG, triglycerides; NVP, nevirapine; and LPV/r, lopinavir-boosted ritonavir.